雷珠单抗玻璃体内注射治疗孤立息肉的2型息肉样脉络膜血管病变  

Clinical efficacy of intravitreal injection of ranibizumab for the treatment of type 2 polypoidal choroidal vasculopathy with isolated polyp

作　　者：邵玲[1] 沈策英 杜敏[1] 赵宏[1] Shao Ling;Shen Ceying;Du Min;Zhao Hong(Department of Ophthalmology,Zhengzhou Municipal Second People’s Hospital,Zhengzhou Eye Institute,Zhengzhou 450006,China)

机构地区：[1]郑州市第二人民医院眼科,郑州市眼科研究所,450006

出　　处：《中华眼外伤职业眼病杂志》2020年第11期815-820,共6页Chinese Journal of Ocular Trauma and Occupational Eye Disease

基　　金：河南省科技攻关项目(2018020739)。

摘　　要：目的:评价雷珠单抗玻璃体内注射治疗孤立息肉的2型息肉样脉络膜血管病变(PCV)的临床效果。方法:回顾性分析郑州市第二人民医院2016年12月至2019年6月孤立息肉的2型PCV 33例(33只眼)的临床资料。采用雷珠单抗玻璃体内注射治疗,每月1次,共6次。观察治疗后3、6及12个月的视力、中央视网膜厚度(CRT)、视网膜色素上皮层(RPE)脱离和息肉的变化。随访12个月。结果:治疗后不同时间点视力均有提高(F=21.502,P<0.05),CRT均有减少(F=296.290,P<0.05)。术后11例(33.3%)RPE脱离逐渐降低。息肉消退率为100%(33/33)。结论:雷珠单抗玻璃体内注射治疗孤立息肉的2型PCV视力明显提高,CRT明显降低,息肉消退率高。Objective To evaluate the clinical efficacy of intravitreal injection of ranibizumab(IVR)for the treatment of type 2 polypoidal choroidal vasculopathy(PCV)with isolated polyp.Methods The clinical data of 33 eyes of 33 cases with type 2 PCV from Dec.2016 to Jun.2019 in Zhengzhou Municipal Second People’s Hospital were analyzed retrospectively.All patients received 6 times of IVR treatment once a month.The visual acuity,central retinal thickness(CRT),pigment epithelial detachment(PED)and polyp change were observed at 3,6,and 12 months after treatment.The follow-up time was 12 months.Results The visual acuity at different times after treatment all improved(F=21.502,P<0.05).CRT was all decreased after treatment(F=296.290,P<0.05).The PED gradually decreased in 11 patients(33.3%)postoperatively.The polyp regression rate was 100%(33/33).Conclusion The efficacy of IVR for the treatment of type 2 PCV is obvious,with the improvement of visual acuity,reduction of CRT and high rate of polyp regression.

关 键 词：血管病变 脉络膜 息肉样 2型 雷珠单抗 玻璃体内注射 肥厚型脉络膜疾病 

分 类 号：R773.4[医药卫生—眼科]